Avintor Consulting

27/08/2026

If your clinical-development strategy begins with a CRO shortlist, you may already be starting too late.

The interesting question is what happened before the shortlist was created.

What did the sponsor know about the asset?

What did the clinical landscape suggest?

Which geographies were genuinely relevant?

Which investigators had demonstrated experience?

What regulatory precedents existed?

And perhaps most importantly:

Was the sponsor choosing a CRO — or simply reacting to a procurement process that had already been defined?

There is a significant difference.

29/07/2026

On the occasion of Guru Pournima, we pause to honor those who shaped our journey.

Every lesson, every challenge, every word of encouragement from a teacher, mentor, colleague, parent, or friend has helped shape who we are today.

At Avintor Consulting, we believe that every meaningful decision begins with learning, and every leader carries a responsibility to become a mentor for others.

As we celebrate Guru Pournima, we express our heartfelt gratitude to everyone who has guided us with wisdom, integrity, and conviction.

May we continue to learn with humility, lead with purpose, and pass forward the light that was once given to us.

Happy Guru Pournima.

With gratitude,
Team Avintor Consulting
Clarity • Context • Conviction

27/07/2026

The budget was cut. The obligations were not. After a difficult financial year, the first instinct is understandable: reduce spend, freeze hiring, delay systems, and ask teams to do more with less. But in life sciences, some work does not become optional because the budget is tighter. Adverse events...

14/05/2026

Some achievements stop you in your tracks.

My daughter Ridhima scored 100/100 in Marketing in her CBSE Class XII Board Examinations — alongside 93 in English and 92 in Mass Media.

But honestly, the number I'm most proud of isn't on the marksheet. It's the quiet discipline she showed getting there. The late nights, the focus, the refusal to settle.

She heads to Mumbai next — and I have a feeling the city is about to meet someone worth watching.

Ridhima, your father couldn't be more proud. 🌟

13/05/2026

With Cipla – I just got recognised as one of their top fans! 🎉

23/04/2026

22/04/2026

When Misalignment Becomes a Regulatory Problem

High team turnover at a CRO created gaps in the inspection storyboard during an MHRA review.

It became a significant finding. The sponsor had to scramble.

The CRO wasn’t incompetent. The alignment was broken — institutional knowledge walked out with every team change, and nobody was governing continuity.

This is what misalignment looks like in a regulatory context. It doesn’t announce itself. It accumulates quietly — and surfaces at the worst possible moment.

You can delegate tasks to a CRO. You cannot delegate responsibility.

Oversight isn’t a checkbox. It’s a system — and building that system before you need it is the only way it works.

21/04/2026

The One-Stop-Shop Myth::

Nearly 8 in 10 pharma and biotech companies now believe the “one-stop-shop” CRO model is no longer cost effective.

And yet — the reflex to consolidate everything under one large vendor persists.
Why? Because complexity is uncomfortable. Multi-vendor ecosystems feel risky.

But here’s what’s actually risky: handing your program to a large CRO whose systems are optimized for their biggest clients — not for your trial.

The sponsors winning right now aren’t the ones with the biggest CRO contract.

They’re the ones with the clearest vendor strategy — right-fit partners, strong governance, and performance visibility that doesn’t depend on the vendor reporting on themselves.

Fit matters more than size. Always has.

20/04/2026

Crisis Calls Are Not Governance

If your sponsor-CRO communication mostly happens during a crisis — you don’t have governance. You have firefighting.

It’s one of the most common patterns in clinical outsourcing: no structured oversight, no outcome-based metrics, and then sudden escalations when things go wrong.

The fix isn’t more meetings. It’s clarity — on decision rights, escalation pathways, and performance indicators that actually reflect trial success.

When communication is predictable and structured, both sides spend less time reacting and more time delivering.

That’s not a radical idea. It’s just alignment — and it’s rarer than it should be.

How does your organization currently handle sponsor-vendor governance? I’m curious what’s working.

19/04/2026

The Hidden Cost of Misalignment

What does misalignment actually cost you?

The Tufts Center for the Study of Drug Development put a number to it: better-aligned drug development models can generate up to $63 million in net financial benefits per program — and save up to 34 months in development time.

34 months. In oncology, that’s not a timeline. That’s lives.

Yet most organizations still evaluate vendor partnerships on rate cards and bid defense presentations — not on operational readiness or alignment depth.

The cost of misalignment is rarely visible on a P&L. It shows up as change orders, inspection findings, team turnover, and delayed approvals.

The question isn’t “Can this partner do the work?”

It’s “Are we actually aligned enough to succeed together?”